pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 15·1 min read
save

Elevance Health to Exit Unsustainable Medicaid Markets Over Next 12-18 Months

Jul 15, 2026·read at STAT ↗Neutral

Elevance Health, the nation's second-largest insurer, said on its Q2 earnings call it will further reduce its Medicaid business in the coming year.

The move comes as several states are preparing to implement work-requirement rules for Medicaid, and Elevance indicated it will exit markets it deems financially unsustainable within 12 to 18 months, following a recent withdrawal from Washington, D.C.

Despite the retreat, the company raised its profit outlook and beat analysts' expectations, reporting roughly $50 billion in revenue and $1.5 billion in profit for the quarter, though profit to shareholders fell 16% year-over-year.

Analysts noted the details were limited, but the strategy signals Elevance's focus on profitability amid rising Medicaid costs.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Elevance plots a Medicaid retreat as costs remain high”

read at STAT ↗
515 words · retrieved Jul 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7RISING
topics
Alzheimer's Disease

related stories

  • 1h agoOpinion: We think a baby’s gut microbiome could be key to lifelong brain healthSTAT
  • Sep 9Mass. governor makes pre-election pitch to biotechs amid warning early-stage start-ups are 'dying'Fierce Biotech
  • Aug 25Roche, Eli Lilly get FDA nod for new Alzheimer’s blood testBioPharma Dive
  • Jul 14STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and moreSTAT
  • Jul 10Opinion: The primary care crisis paradoxSTAT